Ocular Therapeutix 3Q 2026: Revenue $12.87M, EPS ($0.42) — 10-Q Summary
Ocular Therapeutix reported 3Q 2026 revenue of $12.87M, down 11.5% YoY, with a net loss of $94.78M, up 36.5% YoY. The company cited increased R&D costs and higher expenses. DEXTENZA sales declined slightly, while SOL-1 trial met endpoints, with NDA submission expected in Q4 2026.
How this was made

The 30-second read
Why it matters
Earnings miss and higher R&D spend suggest short‑term downside, but upcoming NDA filing may offer a catalyst.
Market read
First‑time earnings disclosure for a micro‑cap biotech; likely to move the stock in after‑hours trading.
What to watch
Potential future NDA filing for SOL-1 could unlock value despite current loss.
Background
The article summarizes Ocular Therapeutix's Q3 2026 10‑Q filing, highlighting financial declines and ongoing clinical trial modifications.
Ticker impact
Q3 2026 results show revenue down 11.5% to $12.87M and net loss widening to $94.78M, with trial updates for SOL-1, SOL-R, and HELIOS-3.
downward pressure as investors price in widening loss and increased R&D spend
Revenue decline and a 36.5% increase in net loss signal weaker near‑term performance; trial setbacks add uncertainty.
Market effects
Biotech sector may see modest pullback as small‑cap trial updates raise risk perception.
U.S. biotech investors could adjust exposure to early‑stage ophthalmic therapies.
Limited; impact confined to niche ophthalmic biotech niche.
Counterpoint
If trial data later prove successful, the stock could rebound sharply on upside potential.
Key entities
- CompanyOcular Therapeutix
US‑listed ophthalmic biotech (ticker OCUL).




